Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more
Calliope Dendrou

Contact information


cdendrou@well.ox.ac.uk


Henry Wellcome Building of Genomic Medicine

Social media

Calliope Dendrou

Dr, Sir Henry Dale Fellow

Our research aims to refine and to develop diagnostic, prognostic and therapeutic strategies for improved healthcare provision to patients with immune-mediated and infectious diseases.

We investigate molecular circuits and cellular mechanisms across tissues and across diseases for the purpose of identifying ‘hubs’ that may be targeted therapeutically via drug repositioning approaches. We are also interrogating the relationship between variation in cell responsiveness and transcriptional kinetics and the spectrum of immune-related diseases spanning malignancies, autoimmunity and infections to help inform risk-benefit analyses in the context of therapeutic targeting.

The Dendrou group is supported by the Wellcome Trust, Royal Society, UKRI Medical Research Council, Chan Zuckerberg Initiative, BBSRC, Rosetrees Trust, Diamond Light Source, John Fell Fund, Janssen, Celsius Therapeutics, and Nimbus Therapeutics.

We are highly collaborative – working locally and internationally with experimental and computational scientists and clinicians. Some of our ongoing research programmes include:

(1)   Investigating the architecture of genetic predisposition across immune-mediated diseases to explore the functional relevance and potential clinical utility of such cross-comparisons; https://www.nature.com/articles/d41586-021-01839-6

(2)   Precision genome editing with tandem autologous transplantation as a therapy for multiple severe immune-mediated diseases; https://gtr.ukri.org/projects?ref=MR%2FT030410%2F1

(3)   Creating cellular atlases across multiple immune-mediated and infectious disorders and malignancies through e.g. the Human Cell Atlas, MAP-JAG, TAURUS, and the Oxford-Janssen Cartography Collaboration

(4)   Mapping human inflammatory responses in ethnically diverse groups using a novel ex vivo lymph node model; https://chanzuckerberg.com/science/programs-resources/single-cell-biology/inflammation-projects/mapping-human-inflammatory-responses-in-ethnically-diverse-groups/

(5)   The Lymph nodE single-cell Genomics AnCestrY (LEGACY) Network: contextualizing the vaccine response of lymph nodes through the creation of an ancestrally diverse single-cell atlas; https://www.well.ox.ac.uk/news/legacy-network-receives-2million-in-funding-from-the-chan-zuckerberg-initiative-for-single-cell-ancestry-vaccine-research